# S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

> **NCT01668719** · PHASE1,PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 142 (actual)

## Conditions studied

- DS Stage I Plasma Cell Myeloma
- DS Stage II Plasma Cell Myeloma
- DS Stage III Plasma Cell Myeloma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone
- **BIOLOGICAL:** Elotuzumab
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01668719
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2020-02-05
- **Final completion:** 2025-09-22
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01668719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01668719, "S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01668719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*